We report the effect of homocysteine on the inactivation of factor Va by activated protein C (APC) using clotting assays, immunoblotting and radiolabeling experiments.
INTRODUCTION
Homocysteine is a non-protein forming, sulfhydryl amino acid derived from the metabolism of methionine. Homocysteine is metabolised in human cells through two pathways of remethylation to methionine and one pathway of transsulfuration to cysteine with cystathionine as an intermediate (1) . Congenital defects in the enzymes involved in methionine metabolism, 5,10-methylenetetrahydrofolate reductase, N5-methyltetrahydrofolate methyltransferase, and cystathionine β-synthase, along with deficiencies in the essential cofactors -folic acid and vitamins B 6 or B 12 , can result in elevated levels of plasma homocysteine. In healthy individuals, plasma total homocysteine -the sum of homocysteine and the homocysteinyl derivatives homocystine and cysteine-homocysteine, whether free or bound to proteins -is between 5-15 µM (2,
3).
A number of case-control and prospective studies have shown that hyperhomocysteinemia, present in 5-7 % of the population, is an independent risk factor for atherosclerotic vascular disease in the coronary (4, 5, 6) , cerebrovascular (7) , and peripheral vessels (8-9), and also for venous thromboembolism (10) (11) (12) (13) .
The relationship(s) between elevated levels of homocysteine in the blood and thrombosis has been a subject of considerable investigative effort, however the mechanisms by which hyperhomocysteinemia leads to increased risk of thrombosis are not clear (14) (15) (16) (17) .
The present study was undertaken to evaluate the ability of homocysteine at concentrations of 1 mM or less to modulate activation of human factor V and inactivation of human factor Va. We examined the effect of homocysteine on these processes using clotting assays and Western blot analyses, along with radiolabeling of factor V by [ 35 S] homocysteine. Our data suggest a potential contributor to the prothrombotic tendency observed in hyperhomocysteinemia.
EXPERIMENTAL PROCEDURES.
Materials.
D,L-homocysteine, L-homocystine, DL-homocysteine thiolactone, and L-cysteine as well as HEPES were purchased from Sigma (St. Louis, MO). 1,2 dioleoyl-sn-glycero-3-
[phospho-L-serine] (sodium salt) (PS) and 1,2 dioleoyl-sn-glycero-3-phosphatidylcholine (PC) were purchased from Avanti (Alabaster, AL). Acrylamide, bis-acrylamide, TEMED, ammonium persulfate, and nitrocellulose were purchased from Bio Rad (Richmond, CA). 7 curves were used to calculate the pseudo first order rate constants. Pseudo first order rate constants are all normalized to constant APC concentration (2.5 nM).
Gel electrophoresis and Western blotting.
Aliquots from the activation/inactivation experiments were withdrawn and quenched in 2% β-mercatoethanol/2 % SDS for electrophoretic analysis. Samples were separated on a 5 to 15% linear gradient gel (SDS-PAGE) under reducing conditions according to Laemmli (39) . Transfer from the gel to nitrocellulose (BioRad, Hercules, CA) was performed as previously described (40). Immunoreactive fragments were detected using the monoclonal antibody αFVa HC No.17, which recognizes an epitope located between residues 307 and 506 in the heavy chain of factor Va (41). Blots were developed using the Renaissance chemiluminescent reagent (Dupont, Boston, MA). Film was developed in a Kodak X-Omat on Reflection film (NEN Life Science Products, Boston, MA).
Densitometry of immunoblots was performed on a Hewlett-Packard ScanJet 4C/T equipped with a transparency adapter for backlighting the X-ray film (Hewlett-Packard, Palo Alto, CA) and analyzed using NIH Image 1.6 (Bethesda, MD).
Activated protein C resistance assay.
Factor V was dialyzed against HBS-Ca 2+ containing 1 mM β-mercaptoethanol or 2 mM 
RESULTS

Activation of factor V by α-thrombin.
There was no significant alteration in α-thrombin activation of factor V after dialysis against 1 mM homocysteine in HBS-Ca 2+ for 2 hours. Homocystine, homocysteine thiolactone, and cysteine incubated with factor V under the same conditions, did not affect activation of factor V by α-thrombin (data not shown).
Inactivation of factor Va by APC in the presence of phospholipids.
Preincubation of factor V with 1 mM homocysteine for 2 hours inhibited the APC anticoagulant effect toward factor Va (Fig. 1) . Factor V was treated with homocysteine at 1 mM, 100 µM, or 30 µM at 4 °C for 2 hours, dialyzed against HBS-Ca +2 for an additional 2 hours, and then activated by α-thrombin. A progressive decrease in the initial rates of APC inactivation of factor Va, generated from the homocysteine-treated factor V, is associated with increasing homocysteine concentrations (Fig. 1) . The rate constant of the APC-catalyzed inactivation of factor Va, generated from factor V treated with 1 mM homocysteine, is about one-third the rate constant for control experiments (Fig.1 ).
To test whether the interference was related to a decrease in APC activity after incubation with homocysteine, APC was preincubated with homocysteine at 1 mM for 30, 60 and factor Va by 2.5 nM APC whether treated with homocysteine or untreated (data not shown). Contrary to previous reports (23,25), we did not observe a direct effect of homocysteine on APC activity per se.
Inactivation of factor Va by APC in the absence of phospholipids.
The cleavage at Arg 306 is phospholipid-dependent, while the cleavage at Arg 506 is enhanced in the presence of phospholipids (30) . In the absence of phospholipids the rate of APC inactivation of factor Va derived from factor V treated with 1 mM homocysteine (above) was significantly delayed compared to controls (Fig. 2) . The approximately 3-fold decrease in the rate constant induced by homocysteine is similar to that observed in the presence of phospholipids. Since the lipid independent inactivation proceeds only through cleavage at Arg 506, the significant impairment of APC inactivation of factor Va without phospholipids indicates that homocysteine must slow cleavage at Arg 506.
Immunoblot analysis of factor Va inactivation by APC.
Factor V (100 nM) was treated with either 1 mM homocysteine, 1 mM homocystine, or The inactivation is homocysteine specific since for factor V preincubated with 1 mM Lcysteine for 2 hours, the inactivation of factor Va by APC was identical to those in control and homocystine experiments (data not shown).
HBS-Ca
Factor V purified from plasma treated with homocysteine.
Human plasma contains a wide range of the sulfhydryl compounds, including cysteine, cysteinylglycine, homocysteine, and glutathione, which are in the reduced (< 5%) or oxidized form, or are protein bound (43). Total plasma concentration of cysteine, the most abundant aminothiol, is around 250 µM with levels of reduced cysteine amounting to 10 µM (43). Moreover, it is known that homocysteine binds to numerous plasma proteins, mainly albumin (plasma concentration 0.5-0.7 mM) at an equimolar ratio. To determine whether addition of homocysteine to normal human plasma would alter the APC sensitivity of factor V subsequently purified from such plasma, human plasma was incubated with homocysteine at 10 mM at 4 °C for 2 hours and then factor V was purified, as described in Methods. Homocysteine added to plasma effectively retarded the inactivation of subsequently purified and α-thrombin activated factor V by APC in the presence of PCPS vesicles (Fig. 4) . The approximately 3 -fold decrease in the rate constant is the same as observed when purified factor V was treated with 1 mM homocysteine ( Fig. 1 ). Slower inactivation of factor Va, derived from factor V purified from plasma treated with homocysteine, was also observed in the absence of phospholipids (data not shown).
Radiolabeling of human factor V with [ 35 S] homocysteine.
To determine whether homocysteine can be incorporated into human factor V, factor V was incubated with 450 µM homocysteine radiolabeling of factor V was complete in less than 90 seconds (data not shown). At concentrations of homocysteine between 10 µM and 450 µM a 5 minute reaction period at room temperature was sufficient to achieve levels of radiolabeling within 15% of those observed after 60 minutes. Figure 6A 
Effects of β-mercaptoethanol (BME).
Since our data suggest that homocysteine is incorporated into factor V through the formation of disulfide bonds we hypothesized that every plasma-derived factor V by guest on July 7, 2017 http://www.jbc.org/ Downloaded from preparation would reflect some level of derivatization with homocysteine and thus some impairment with respect to APC inactivation. To test this hypothesis we dialyzed factor V against 1 mM β-mercaptoethanol for 2 hours. Factor Va, derived from the thiol-reduced factor V, was inactivated by APC about 50 % more rapidly than the control (Fig. 7) .
APC-resistance assay performed in plasmas containing various mixtures of reduced (FV BME ) and homocysteinylated (FV HCY ) factor V.
A series of reconstituted plasmas were generated with varying proportions of partially reduced factor V (FV BME ) and homocysteinylated factor V (FV HCY ) (see Methods) and tested in an APC resistance assay format. Clotting times for each factor V mixture were measured following incubation in the presence or absence of 1 nM APC. The clotting time for each factor V mixture was then plotted against the percent of reduced factor V (FV BME ) present in that mixture. Figure 8 shows the results of such an experiment. The composition of the factor V mixture had no effect on the rate of clot formation in the absence of APC (closed circles). However with APC, clotting times in those same mixtures increased as a function of the percentage of FV BME present: from 56 seconds with 0% FV BME /100% FV HCY to 89 seconds with 100% FV BME /0% FV HCY (open circles).
A pooled plasma obtained from normal individuals gave clotting times of 46 seconds in the absence of APC and 85 seconds in the presence of APC, corresponding to a FV BME /FV HCY composition of 88%/12% (Fig. 8) .
Plasmas from four individuals (see Methods) with homocysteine levels of 40, 44, 76 and 80 µM were then tested in this assay format (Fig. 8) . In the absence of APC, clotting times for patient plasmas always fell between 40-45 seconds, the same range as observed with the mixtures constructed in factor V deficient plasma (Fig. 8) . In the presence of APC, clotting times for the pair with 40 µM levels of homocysteine averaged 79 seconds, corresponding to a FV BME /FV HCY distribution of 68%/32%; clotting times for the plasmas with approximately 80 µM homocysteine averaged 71 seconds, corresponding to a FV BME /FV HCY composition of 44%/56%. Thus plasmas with higher homocysteine levels behave in the APC resistance assay as mixtures with a higher proportion of FV HCY .
DISCUSSION
We present evidence that, in vitro, homocysteine treatment of factor V can protect α-thrombin derived factor Va from inactivation by APC. This effect is observed at concentrations of homocysteine as low as 30 µM, similar to those found in the blood of patients with "moderate hyperhomocysteinemia". As the homocysteine concentration used to treat factor V increases, impairment of APC-mediated proteolysis of human factor Va is more evident (Fig 1) . Our data indicate that the rate of APC cleavage at Arg 506 of homocysteinylated factor Va is diminished about 2.5 fold. (Fig 2) . The magnitude of this inactivation impairment is similar to that observed when APC inactivation of factor V Leiden is assessed in a function based assay (45). factor V, produced in vitro by treating purified factor V from pooled normal plasma with β-mercaptoethanol (FV BME ), and representing the source of factor Va most rapidly inactivated by APC (Fig. 7) . The other component is homocysteine modified factor V, generated in vitro by treating factor V with 2 mM homocysteine (FV HCY ), representing the source of "impaired" factor Va. The rate constant for the latters' inactivation by APC is approximately 25% that for unmodified factor Va. Plasma factor V may then be conceived of as a mixture of these species, the amounts of each being a function of plasma homocysteine and factor V concentrations and the equilibrium constant. When such mixed populations were systematically constructed from FV BME and FV HCY stocks and tested in an APC resistance assay format, clotting times increased in a linear manner with increasing representation by FV BME in the factor V mixture (Fig. 8) . This curve was Since platelets contain factor V that is secreted upon platelet activation, the procoagulant activity of homocysteine through modification of platelet factor V may be important in regulating coagulation reactions at the site of vascular injury. If this is the case, the property of homocysteine described here could also contribute to an increased risk of arterial thrombosis reported in patients with hyperhomocysteinemia. In summary, our results indicate that homocysteine markedly impairs the APC-mediated inactivation of factor Va. This effect is likely to be the consequence of modification of factor V through attachment of homocysteine to free cysteine(s). Our study strongly suggests that at the least the action of homocysteine on factor Va inactivation is specific, involves the entire molecule and takes place at submillimolar homocysteine concentrations. The novel pathophysiological mechanism reported here may partly explain the thrombotic tendency observed in patients with hyperhomocysteinemia. Although the relationship between the pathology of hyperhomocysteinemia and APC resistance is by no means established by the present work, our data do indicate that homocysteine modification of factor V is a potential confounder of current APC resistance assays. 
Figure 7.
Effects of β-mercaptoethanol (BME). Factor V was dialyzed against HBSCa 2+ with 1 mM BME (l) or without (¡), as described in Methods. Factor V (100 nM)
was activated with α-thrombin (0.5 nM), followed by addition of hirudin (2 nM 
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